Multiple sclerosis has one of the longest HBOT research histories. A wave of trials ran in the 1980s and 1990s. The pattern across those trials was consistent and largely negative.
This page lays out that history honestly. The promise drove patient demand, but the data did not match. MS bodies have stopped recommending the approach.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for MS |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for MS |
| Insurance coverage | Out-of-pocket only at most clinics |
| Typical out-of-pocket | $5,000-$12,000 for a 20- to 40-session course |
| Evidence grade | Negative — 12 trials, no consistent benefit |
The evidence
MS HBOT was tested heavily in the 1980s. A dozen randomized trials ran across the US, UK, and Europe. The pooled signal across those trials was weak to absent.
The Fischer and colleagues 1983 NEJM trial, PMID 6336824 was the first major US trial. Forty patients with chronic MS received either pure oxygen at 2 ATA or a 10% oxygen mix as placebo. The HBOT arm showed slightly less worsening on one scale but no change on disability or relapse rates.
The Fischer 1983 paper drove enthusiasm. Patient demand soared. A wave of replication trials followed.
The Wiles and colleagues 1986 placebo-controlled trial, PMC 1032548 ran a 120-patient double-blind trial. The HBOT arm did not differ from the placebo arm on any clinical measure.
The Bouachour and colleagues 1987 chronic MS trial, PMID 3534267 followed the same pattern. Initial small studies hinted at benefit. Larger and better-controlled work did not confirm the signal.
The Worthington 1985 series on chronic MS used a non-randomized crossover in 51 patients. Some small improvements appeared on peak flow and finger tapping, but walking and balance improved more in the placebo phase. The pattern is hard to read as a treatment effect.
The Kleijnen and Knipschild 1995 review, PMID 7639061 pooled 14 controlled trials. Only one — the original Fischer 1983 paper — showed a result favoring HBOT. The other trials of reasonable to high quality did not show positive effects.
The Bennett and Heard 2010 CNS Neuroscience review, PMID 20415839 was the most comprehensive synthesis. The authors used Cochrane methods to pool 12 randomized trials done between 1983 and 1987. The meta-analysis found no clinically significant benefit from HBOT in MS.
The UHMS position paper on MS and HBOT explicitly does NOT recommend HBOT for MS. The position has stood since the 1980s wave of negative trials.
The Bennett 2014 Cochrane on acute stroke, 2014, PMID 25387992 used the same methods for a different condition. The MS conclusion in the prior synthesis was unchanged.
The pattern is consistent across 40 years. Small early studies hinted at benefit, but larger and better-controlled trials did not confirm. The 2010 Cochrane-style synthesis closed the case.
Why people still pursue this anyway
MS is a hard disease. Disease-modifying drugs slow progression but do not reverse damage. Patients in chronic progressive phases often run out of options.
That desperation drives interest in any plausible therapy. The 1980s wave of HBOT enthusiasm is still echoed in clinic marketing. Wellness chains including Restore Hyper Wellness and many small operators still offer MS protocols.
Some patients report symptom relief from HBOT. Whether that is HBOT working or a placebo effect is unclear. The randomized trials say it is mostly placebo.
The honest gap is wide. Forty years of trials say no consistent benefit, yet clinic ads still promise hope. Patients deserve to weigh that against a five-figure spend.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing breakdown of the leading HBOT chain and our analysis of institutional silence on HBOT.
What MS guidelines actually say
The National Multiple Sclerosis Society does not recommend HBOT for MS. The position has stood for decades.
The American Academy of Neurology MS practice guidelines do not include HBOT as a recommended therapy. The European Committee for Treatment and Research in MS also leaves HBOT off the list.
UHMS does not list MS on its 14 approved indications. The UHMS HBO indications page, 2024 is the source of truth.
Major academic MS centers do not offer HBOT for MS. Their wound care and dive medicine chambers run for the approved uses only.
Cost versus evidence
A 20- to 40-session course at a wellness clinic runs $5,000 to $12,000. Premium chain packages can run higher.
Patients face this cost without insurance support. HSA and FSA accounts may or may not accept the claim, depending on plan rules.
That price stacks against 12 randomized trials showing no clinical benefit. The math poses a hard question — is a $5,000-$12,000 spend justified against that level of evidence?
The framing is not that no patient should try this. The framing is that the evidence base is one of the cleanest negatives in the HBOT literature.
What to ask your neurologist
Patients weighing HBOT for MS can ask a few key questions. Each cuts through clinic marketing.
What did the 12 randomized trials from 1983-1987 actually show — the answer is "no consistent benefit." What did the 2010 Bennett and Heard review conclude — the answer is "no clinically significant benefit." Does the National Multiple Sclerosis Society recommend HBOT — the answer is "no."
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. MS protocols historically used medical-grade hard chambers from Sechrist Industries and Perry Baromedical, not the soft 1.3 ATA chambers from OxyHealth or Summit to Sea at wellness sites.
Distinguishing from FDA-approved uses
MS sits very differently from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten more — all have decades of backing data and multi-center trials.
Our diabetic foot ulcer evidence atlas and carbon monoxide poisoning evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, settled mechanism, insurance coverage.
MS has the opposite pattern — forty years of negative trials and no specialty body endorsement. The honest call is not just "investigational." The honest call is "tested and largely failed."
Frequently asked questions
Is HBOT FDA-approved for MS?
No. The FDA recognizes 14 conditions for HBOT and MS is not among them. The UHMS approved indications list, current 2024, also does not include MS.
What did the 12 MS trials actually show?
The Bennett and Heard 2010 review pooled 12 randomized trials done between 1983 and 1987. The meta-analysis found no clinically significant benefit from HBOT in MS. Small early studies hinted at benefit. Larger and better-controlled work did not confirm.
Will Medicare or insurance cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. MS is out-of-pocket at almost all clinics offering this protocol.
How much does a course cost?
Most wellness clinics charge $250 to $400 per session. A 20- to 40-session course runs $5,000 to $12,000. Premium chain packages can run higher.
Does the National MS Society recommend HBOT?
No. The National Multiple Sclerosis Society does not recommend HBOT for MS. The American Academy of Neurology MS guidelines also do not include HBOT.
Sources
- Fischer and colleagues NEJM 1983, PMID 6336824
- Kleijnen and Knipschild meta-analysis 1995, PMID 7639061
- Wiles and colleagues placebo-controlled trial 1986
- Bouachour and colleagues 1987, PMID 3534267
- Worthington series 1985, PMID 3891920
- Bennett and Heard CNS Neuroscience 2010, PMID 20415839
- UHMS Position Paper on MS and HBOT
- Bennett Cochrane acute stroke 2014, PMID 25387992
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for MS is an investigational off-label use without FDA approval, and the evidence base is one of the cleanest negatives in the HBOT literature. Standard MS care including disease-modifying therapies remains the guideline-recommended path. Talk to your neurologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose, treat, or substitute for professional medical care.